What You Should Know:
– iRhythm Technologies, a digital health leader focused on detecting, predicting, and preventing disease announced a strategic partnership with Lucem Health, an AI-driven early disease detection.
– The strategic collaboration aims to accelerate the early identification of undiagnosed arrhythmias in patient populations with an elevated risk for the condition.
Shift from Reactive to Predictive Care
Traditional care models often rely on reactive diagnosis, which can leave arrhythmias undetected until a major event like a stroke or hospitalization occurs. This partnership brings together Lucem Health’s Reveal AI-powered early disease detection platform and iRhythm’s proven diagnostic service to shift this paradigm. By identifying risk earlier and enabling targeted cardiac monitoring, the goal is to help clinicians intervene sooner, improve outcomes for at-risk patient populations, and support scalable, data-driven strategies for health systems focused on value-based care.
The strategic partnership, which includes a direct investment from iRhythm in Lucem Health, reflects a shared commitment to advancing predictive innovation for population-level impact.
The Case for Earlier Detection
Cardiac arrhythmias, conditions where the heart beats irregularly, affect roughly 1 in 20 U.S. adults. If left undetected and untreated, they can lead to stroke, heart failure, or death, making early identification critical. New research highlights a significant opportunity to detect these conditions earlier in at-risk populations, particularly around key clinical turning points in disease progression, such as in patients with T2D.
Predictive AI Solution for Smarter Arrhythmia Detection
The first commercial offering from the collaboration is an exclusive, AI-powered solution that analyzes subtle patterns in clinical and EHR data to identify elevated arrhythmia risk. It targets individuals with Type 2 diabetes (T2D), chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), and coronary artery disease (CAD), who might not otherwise be flagged for ambulatory cardiac monitoring. This offering enables healthcare organizations to proactively pinpoint patients with these conditions who could benefit from earlier monitoring and intervention.
Once identified, appropriate patients can be monitored using iRhythm’s clinically proven Zio® ECG monitors and service. The Zio ECG device is worn for up to 14 days, providing continuous, uninterrupted heart rhythm monitoring. The end-to-end service, powered by an advanced FDA-cleared AI algorithm, delivers actionable insights curated by qualified cardiac technicians to help clinicians make the right diagnosis and support timely care.
“Healthcare is entering an era where the goal is no longer just to detect disease, but to predict it,” said Quentin Blackford, iRhythm President and CEO. “Together with Lucem Health, iRhythm is helping lead a new way forward in care, with the goal of reaching patients before symptoms surface and before complications arise. We believe more than 27 million people in the U.S. alone could benefit from proactive cardiac monitoring — and this is just the beginning.”
